Pfizer Inc Reduces Stock Holdings in NextCure, Inc. $NXTC

Pfizer Inc lowered its holdings in shares of NextCure, Inc. (NASDAQ:NXTC) by 91.7% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 157,646 shares of the company’s stock after selling 1,734,117 shares during the quarter. NextCure makes up approximately 0.0% of Pfizer Inc’s holdings, making the stock its 19th biggest position. Pfizer Inc owned about 5.88% of NextCure worth $73,000 at the end of the most recent quarter.

NextCure Stock Performance

Shares of NextCure stock opened at $10.15 on Tuesday. The company has a fifty day moving average of $7.82 and a 200 day moving average of $6.26. NextCure, Inc. has a fifty-two week low of $2.69 and a fifty-two week high of $16.80. The company has a market capitalization of $27.20 million, a P/E ratio of -0.42 and a beta of 1.48.

NextCure (NASDAQ:NXTC) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($3.22) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($4.06) by $0.84. Analysts forecast that NextCure, Inc. will post -1.87 EPS for the current year.

Analyst Ratings Changes

A number of analysts have commented on NXTC shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of NextCure in a report on Friday, October 31st. LADENBURG THALM/SH SH upgraded NextCure from a “neutral” rating to a “buy” rating and set a $18.00 price objective for the company in a research note on Friday, November 7th. Three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, NextCure currently has an average rating of “Moderate Buy” and an average target price of $23.00.

NextCure Company Profile

NextCure, Inc, a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells.